TollCyto Therapeutics develops precision‑engineered oncolytic herpesvirus therapies, including HSV5‑ Sign up to read more
| Allotment | Filed | Share Class | Round Size | Round Type |
|---|---|---|---|---|
2026-07-28 | £290k |
Companies with the most similar business descriptions.
Accounts not filed
Capital raised per employee divides the equity TOLLCYTO THERAPEUTICS LTD raised in the last six months by the headcount in its most recent filed accounts. It is a rough read on how capital-intensive the business is: a high figure means the company is raising a lot relative to the number of people it employs, which is typical of hardware, biotech and other research-heavy businesses. Headcount comes from annual accounts and so lags the funding date, often by a year or more.